000124434 001__ 124434
000124434 005__ 20240228145514.0
000124434 0247_ $$2doi$$a10.1002/gcc.22467
000124434 0247_ $$2pmid$$apmid:28437838
000124434 0247_ $$2ISSN$$a1045-2257
000124434 0247_ $$2ISSN$$a1098-2264
000124434 0247_ $$2altmetric$$aaltmetric:19548465
000124434 037__ $$aDKFZ-2017-01311
000124434 041__ $$aeng
000124434 082__ $$a570
000124434 1001_ $$aMargolin-Miller, Yulia$$b0
000124434 245__ $$aPrognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
000124434 260__ $$aNew York, NY$$bWiley-Liss$$c2017
000124434 3367_ $$2DRIVER$$aarticle
000124434 3367_ $$2DataCite$$aOutput Types/Journal article
000124434 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510751593_10596
000124434 3367_ $$2BibTeX$$aARTICLE
000124434 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124434 3367_ $$00$$2EndNote$$aJournal Article
000124434 520__ $$aEpendymoma is a malignant pediatric brain tumor, often incurable under the current treatment regimen. We aimed to evaluate the expression of microRNAs (miRs) in pediatric ependymoma tumors in an attempt to identify prognostic molecular markers which would lead to potential therapeutic targets. Following miR-array expression analysis, we focused on 9 miRs that correlated with relapse which were further validated by quantitative real-time PCR (qRT-PCR) in a cohort of 67 patients. Western blotting and immunohistochemistry were used to measure target protein expression in 20 and 34 tumor samples, respectively. High expression of miR-124-3p significantly correlated with the lower progression-free survival (PFS) of 16% compared to 67% in those expressing low levels (P = .002). Interestingly, in the group of patients with local disease (n = 56) expression levels of this miR distinguished 2 subgroups with a significantly different outcome (P = .001). miR-124-3p was identified as an independent prognostic factor of relapse in the multivariate analysis performed in the whole cohort and in the group with localized disease. In the localized group, a patient expressing high levels of miR-124-3p had a 4.1-fold increased risk for relapse (P = .005). We demonstrated the direct binding of miR-124-3p to its target TP53INP1. Negative TP53INP1 protein levels correlated with a poor outcome (P = .034). We propose miR-124-3p and TP53INP1 as new biomarkers for prognostic stratification that may be possible therapeutic targets for ependymoma.
000124434 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000124434 588__ $$aDataset connected to CrossRef, PubMed,
000124434 7001_ $$aYanichkin, Natalia$$b1
000124434 7001_ $$aShichrur, Keren$$b2
000124434 7001_ $$aToledano, Helen$$b3
000124434 7001_ $$aOhali, Anat$$b4
000124434 7001_ $$0P:(DE-HGF)0$$aTzaridis, Theophilos$$b5
000124434 7001_ $$aMichowitz, Shalom$$b6
000124434 7001_ $$aFichman-Horn, Suzana$$b7
000124434 7001_ $$aFeinmesser, Meora$$b8
000124434 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b9
000124434 7001_ $$0P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aWitt, Hendrik$$b10$$udkfz
000124434 7001_ $$aTabori, Uri$$b11
000124434 7001_ $$aBouffet, Eric$$b12
000124434 7001_ $$aRamaswamy, Vijay$$b13
000124434 7001_ $$aHawkins, Cynthia$$b14
000124434 7001_ $$aTaylor, Michael D$$b15
000124434 7001_ $$aYaniv, Isaac$$b16
000124434 7001_ $$00000-0002-5409-9320$$aAvigad, Smadar$$b17
000124434 773__ $$0PERI:(DE-600)1492641-6$$a10.1002/gcc.22467$$gVol. 56, no. 8, p. 639 - 650$$n8$$p639 - 650$$tGenes, chromosomes & cancer$$v56$$x1045-2257$$y2017
000124434 909CO $$ooai:inrepo02.dkfz.de:124434$$pVDB
000124434 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000124434 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000124434 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000124434 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000124434 9141_ $$y2017
000124434 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000124434 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGENE CHROMOSOME CANC : 2015
000124434 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124434 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124434 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124434 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124434 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000124434 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124434 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124434 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000124434 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124434 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000124434 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000124434 980__ $$ajournal
000124434 980__ $$aVDB
000124434 980__ $$aI:(DE-He78)B062-20160331
000124434 980__ $$aUNRESTRICTED